TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8684694

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel (0.5 mg) for cervical ripening and intravaginal PGE2 gel (2 mg) for induction of labor
Number of subjects: 75

Group type: COMPARATOR
Intervention: i.v. Oxytocin+Amniotomy for induction of labor
Number of subjects: 75
Study: 1880796

Group type: EXPERIMENTAL
Intervention: Tryptophan (50 mg/kg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7035184

Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg b.i.d.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30890197

Group type: EXPERIMENTAL
Intervention: Amber lenses intervention (to block blue light)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clear lenses intervention (control)
Number of subjects: 14
Study: 29045610

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I concentration above the upper reference limit (URL)
Number of subjects: 4748

Group type: COMPARATOR
Intervention: Troponin concentrations < URL
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: Adding troponin to a model with demographic, cardiovascular risk factor, and clinical variables
Number of subjects: 4748
Study: 27091008

Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 2493

Group type: COMPARATOR
Intervention: Injectable progestin contraception (IPC)
Number of subjects: 2493
Study: 24678280

Group type: EXPERIMENTAL
Intervention: Curcumin (1 g daily for 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (matched control for 4 weeks)
Number of subjects: 30
Study: 22646140

Group type: COMPARATOR
Intervention: Standard regimen of intravenous proton pump inhibitors (PPIs)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: High-dose intensive intravenous regimen of PPIs
Number of subjects: 875

Group type: COMPARATOR
Intervention: Standard regimen of intravenous PPIs
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Early endoscopy
Number of subjects: 875

Group type: COMPARATOR
Intervention: Late endoscopy
Number of subjects: 875
Study: 20219293

Group type: EXPERIMENTAL
Intervention: Chestnut's Bloomington Outpatient Treatment (CBOP) without ACC
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Chestnut's Bloomington Outpatient Treatment (CBOP) with ACC
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) without ACC
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavior Therapy‐7 session model (MET/CBT7) with ACC
Number of subjects: 320
Study: 17980528

Group type: EXPERIMENTAL
Intervention: Bu‐zhong‐yi‐qi‐tang
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ping‐wei‐san
Number of subjects: 60
Study: 15901745

Group type: EXPERIMENTAL
Intervention: Progesterone (PG) intravenous infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 36
Study: 12468601

Group type: EXPERIMENTAL
Intervention: Butter (40 g fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olive oil (40 g fat)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sunflower oil (40 g fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-fat test meal (0 g fat)
Number of subjects: 10
Study: 12084522

Group type: EXPERIMENTAL
Intervention: Hyperventilation in group 1 (14 patients)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hyperventilation in group 2 (9 patients)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hyperventilation in group 3 (8 patients)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Naloxone administration
Number of subjects: 31
Study: 9793768

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.02% solution, applied for 3 minutes)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (surgical excision only)
Number of subjects: 17
Study: 7867870

Group type: EXPERIMENTAL
Intervention: Orlistat 80 mg, three times daily for 8 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: High fibre diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intracellular fat
Number of subjects: 32
Study: 2916939

Group type: EXPERIMENTAL
Intervention: Surgical resection with postoperative treatment of fluorouracil and hepatic irradiation
Number of subjects: 356

Group type: COMPARATOR
Intervention: Surgical resection only (observation)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 356
Study: 356249

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren) 25 mg t.i.d. for 14 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Naproxen 250 mg b.i.d. for 14 days
Number of subjects: 120
Study: 31719214

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis MB40 at 5 × 10^9 CFU once daily for 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis MB40
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31279724

Group type: EXPERIMENTAL
Intervention: National College Health Assessment (N = 610,543)
Number of subjects: 788235

Group type: EXPERIMENTAL
Intervention: Healthy Minds Study (N = 177,692)
Number of subjects: 788235

Group type: EXPERIMENTAL
Intervention: Anger, low flourishing, and suicide plans (assessed in only one dataset)
Number of subjects: 788235
Study: 27910718

Group type: EXPERIMENTAL
Intervention: 40% CHO/45% fat diet (higher fat diet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 60% CHO/25% fat diet (lower fat diet)
Number of subjects: 0
Study: 25979191

Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Symphysis group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ramus group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both harvesting techniques
Number of subjects: 75
Study: 23931537

Group type: EXPERIMENTAL
Intervention: Weak intervention (hints with 66% of incorrect interpretations and 33% of correct interpretations)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Strong intervention (hints with 80% of incorrect interpretations and 20% of correct interpretations)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no hints)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Weak and strong intervention groups (combined)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 117
Study: 21303619

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor during the intervention period
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DIABTel telemedicine system
Number of subjects: 10
Study: 19522369

Group type: EXPERIMENTAL
Intervention: Viscoelastic foam cushions (5 different types tested)
Number of subjects: 35
Study: 17093179

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) breakfast
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-Carbohydrate (HC) breakfast
Number of subjects: 8
Study: 14977667

Group type: COMPARATOR
Intervention: No preconditioning (group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cyclic preconditioning (group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Isometric preconditioning (group 3)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isometric preconditioning (80 N) for AT and HT grafts alone (no fixation)
Number of subjects: 42
Study: 11708938

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 9257670

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Iloprost (8 hours/day i.v. infusion)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No antiplatelet medication (Control)
Number of subjects: 43
Study: 8217179

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 0.03 mg/kg
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 69
Study: 3620398

Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin protocol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose oxytocin protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no oxytocin)
Number of subjects: 60
Study: 31623764

Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 4146

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 4146
Study: 30018242

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 13
Study: 27195814

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (SBP target <120 mm Hg, n=1317)
Number of subjects: 2636

Group type: COMPARATOR
Intervention: Standard treatment group (SBP target <140 mm Hg, n=1319)
Number of subjects: 2636

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 2636

Group type: COMPARATOR
Intervention: Standard treatment group
Number of subjects: 2636
Study: 24968148

Group type: EXPERIMENTAL
Intervention: 200 μM capsaicin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dysphagia severity
Number of subjects: 20
Study: 23241939

Group type: EXPERIMENTAL
Intervention: Forskolin and rutin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20523971

Group type: EXPERIMENTAL
Intervention: 60 g glucose administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 g glucose administration
Number of subjects: 0
Study: 18554201

Group type: EXPERIMENTAL
Intervention: Ejection Fraction ≤ 35%
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Ejection Fraction 36-49%
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Ejection Fraction ≥ 50%
Number of subjects: 1135
Study: 15683479

Group type: EXPERIMENTAL
Intervention: Biphasic cardioversion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Monophasic cardioversion
Number of subjects: 48
Study: 12586452

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catecholamine depletion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham depletion
Number of subjects: 0
Study: 10773778

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) - 8 1-hour sessions of individual cognitive therapy for 6 weeks, followed by 6 2-hour sessions of social skills training (SST) in group weekly
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT) - after switching group 2 to CBT
Number of subjects: 67

Group type: COMPARATOR
Intervention: Supportive therapy (ST) - 12 weeks (6 half-hour sessions)
Number of subjects: 67
Study: 8873158

Group type: EXPERIMENTAL
Intervention: Standard dose neuraxis irradiation (3,600 cGy/20 fractions)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Reduced neuraxis irradiation (2,340 cGy/13 fractions)
Number of subjects: 126
Study: 1736336

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: 300 mg ranitidine at bedtime for 2 weeks
Number of subjects: 60
Study: 6093656

Group type: EXPERIMENTAL
Intervention: Aminophylline (9 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: No active drug intervention
Number of subjects: 18
Study: 3094459

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combining MMC with Tegaful
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Systemic intravenous administration of MMC 4 mg, two times a week for three weeks, combined with prolonged oral administration of Tegaful 800 mg/day for more than three months
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Intra-operative local intra vessel administration of MMC 10 mg
Number of subjects: 1156
Study: 30571337

Group type: EXPERIMENTAL
Intervention: Periprocedural stroke
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol myocardial infarction (MI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarker-only event
Number of subjects: 0
Study: 27182068

Group type: EXPERIMENTAL
Intervention: Dance intervention (10 weeks, 45 min/week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active control (nondance program)
Number of subjects: 24
Study: 25795413

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23782447

Group type: EXPERIMENTAL
Intervention: Cerebral near-infrared spectroscopy (NIRS) oximetry plus a clinical treatment guideline
Number of subjects: 166

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Cerebral ultrasound score
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Interburst intervals on an amplitude‐integrated electroencephalogram at 64 hours of life
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental outcome at 2 years corrected age
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging at term
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Blood biomarkers at 6 and 64 hours after birth
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Mortality at term date
Number of subjects: 166
Study: 20886791

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with acupoint sticking therapy (observation group)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Jiawei Mojie tablet (control group)
Number of subjects: 73
Study: 18991816

Group type: EXPERIMENTAL
Intervention: Active treatment with target levels of glycemia (n=41)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients with 1% lowering of HbA1c (n=18)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients with HbA1c lowering < 1% (n=26)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of patients with increase of HbA1c (n=31)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group with usual treatment (n=40)
Number of subjects: 81
Study: 16586308

Group type: EXPERIMENTAL
Intervention: Acute psychiatric day hospital care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 0
Study: 11821459

Group type: EXPERIMENTAL
Intervention: 3-day residential communication skills course
Number of subjects: 93
Study: 9661554

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 5 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 7.5 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 10 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 12.5 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 15 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: i.v. ketorolac 30 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: i.v. saline (control group)
Number of subjects: 70
Study: 7947208

Group type: EXPERIMENTAL
Intervention: Topically applied calcipotriol
Number of subjects: 6
Study: 2534042

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study: 336653

Group type: EXPERIMENTAL
Intervention: Carbuterol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 15
Study: 29420232

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Skin incisions only (sham control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 44
Study: 26899531

Group type: EXPERIMENTAL
Intervention: Safe-storage container plus water pasteurization indicator
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Safe-storage container alone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 24401291

Group type: EXPERIMENTAL
Intervention: 2.5 g of bioactive collagen peptide (BCP) VERISOL® once daily for 8 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 2.5 g of bioactive collagen peptide (BCP) VERISOL® after 8 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo after 8 weeks
Number of subjects: 114
Study: 21207071

Group type: EXPERIMENTAL
Intervention: 6-month, facility- and home-based viniyoga intervention (n = 32)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control group (n = 31)
Number of subjects: 63
Study: 20386339

Group type: EXPERIMENTAL
Intervention: Multistation proprioceptive exercise program
Number of subjects: 232

Group type: COMPARATOR
Intervention: Normal workout routines (Control)
Number of subjects: 232
Study: 18227295

Group type: EXPERIMENTAL
Intervention: Patient-specific heparin concentration-based protocol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard weight-based heparin dose (400 U/kg)
Number of subjects: 25
Study: 15707467

Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis) Turbuhaler 4.5 microg
Number of subjects: 18124

Group type: COMPARATOR
Intervention: Salbutamol 200 microg
Number of subjects: 18124
Study: 14689390

Group type: EXPERIMENTAL
Intervention: Concept mapping
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional nursing care plans
Number of subjects: 76
Study: 10365879

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 7491881

Group type: EXPERIMENTAL
Intervention: Diet high in aspartame
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diet high in sucrose
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diet high in saccharin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Baseline hemolysate samples
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: One subject with low hydrolase activity
Number of subjects: 48
Study: 1962778

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for stage II and IIIA nonsquamous cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant therapy for stage I disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant radiation therapy for stage II and IIIA squamous cell carcinoma
Number of subjects: 0
Study: 6448429

Group type: EXPERIMENTAL
Intervention: naproxen (500 mg initially, followed by 250 mg as needed, max 1250 mg daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 26
Study: 30180057

Group type: EXPERIMENTAL
Intervention: CT + CTA
Number of subjects: 2831

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 2831
Study: 27823703

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (n=24)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n=21)
Number of subjects: 45
Study: 25230288

Group type: EXPERIMENTAL
Intervention: HIV prevention counseling intervention delivered by lay counselors using motivational interviewing strategies based on the Information‐Motivation‐Behavioral (IMB) Skills model during routine clinical care.
Number of subjects: 1891

Group type: COMPARATOR
Intervention: Standard-of-care counseling.
Number of subjects: 1891
Study: 22218627

Group type: EXPERIMENTAL
Intervention: Mailed educational materials and a fecal immunochemical test (FIT)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Mailed educational materials and a fecal immunochemical test (FIT) plus a telephone call
Number of subjects: 373
Study: 20408059

Group type: EXPERIMENTAL
Intervention: Mindfulness-based TC (MBTC) intervention
Number of subjects: 393

Group type: COMPARATOR
Intervention: Therapeutic community (TC) control group
Number of subjects: 393
Study: 17565285

Group type: EXPERIMENTAL
Intervention: Familiar odor (vanillin)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Unfamiliar odor
Number of subjects: 44

Group type: COMPARATOR
Intervention: No odor
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Familiar odor learned via mother
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Familiar odor learned via crib
Number of subjects: 44
Study: 16111600

Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic dose assessment (I-FL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic dose assessment (I-FL) for I-125
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intraoperative fluoroscopic dose assessment (I-FL) for Pd-103
Number of subjects: 26
Study: 11825631

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin administration (SC)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion (IV)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routinely managed group (RM)
Number of subjects: 62
Study: 10451565

Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC) 125 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen (I) 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 8737333

Group type: EXPERIMENTAL
Intervention: Consultation in the GUM clinic
Number of subjects: 98

Group type: COMPARATOR
Intervention: Consultation in the FPC
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: GUM testing in the GUM clinic
Number of subjects: 98

Group type: COMPARATOR
Intervention: GUM testing in the FPC
Number of subjects: 98
Study: 1878611

Group type: EXPERIMENTAL
Intervention: Natural killer (NK) cell activity
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 90
Study: 7128186

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30903885

Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 300
Study: 28282789

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab and panitumumab (arm I)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Erlotinib plus placebo (arm II)
Number of subjects: 297
Study: 26937005

Group type: EXPERIMENTAL
Intervention: Task-specific training group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Active-training control group
Number of subjects: 100